Treatment and rehabilitation of Long COVID: A scope of the literature.: Update January 2023

Gary Austin Raine; Claire Louise Khouja; Meena Khatwa; Melissa Harden; Katy Sutcliffe; Amanda Jayne Sowden

Treatment and rehabilitation of Long COVID: A scope of the literature. Update January 2023

Gary Austin Raine, Claire Louise Khouja, Meena Khatwa, Melissa Harden, Katy Sutcliffe, Amanda Jayne Sowden

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Abstract

Summary
• We identified 12 randomised controlled trials published since September 2022 that were focused on Long COVID treatment or rehabilitation. Across our three reports produced to date, we have identified and assessed 37 trials published between January and December 2022.
• Half of the trials included in this update had a primary focus on treating persistent problems with respiratory function and physical fitness (n=6). Other trials focused on olfactory dysfunction (n=2); and cognitive problems and long-term fatigue (n=1). Three trials evaluated non-specific interventions for treating Long COVID symptoms (n=3). • Seven trials were rated positively for at least 11 out of the 13 criteria that we assessed.

Original language	English
Place of Publication	London
Publisher	EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.
Commissioning body	NIHR Policy Research Programme
Number of pages	24
ISBN (Electronic)	978-1-911605-37-9
Publication status	Published - Jan 2023

Access to Document

LC_treatment3_Jan_final-2
Authors of the systematic reviews on the EPPI Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise, users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.
Final published version, 598 KBLicence: CC BY-NC

Cite this

@book{f36d314dae134fd28478f0d241c016b6,

title = "Treatment and rehabilitation of Long COVID: A scope of the literature.: Update January 2023",

abstract = "Summary• We identified 12 randomised controlled trials published since September 2022 that were focused on Long COVID treatment or rehabilitation. Across our three reports produced to date, we have identified and assessed 37 trials published between January and December 2022.• Half of the trials included in this update had a primary focus on treating persistent problems with respiratory function and physical fitness (n=6). Other trials focused on olfactory dysfunction (n=2); and cognitive problems and long-term fatigue (n=1). Three trials evaluated non-specific interventions for treating Long COVID symptoms (n=3). • Seven trials were rated positively for at least 11 out of the 13 criteria that we assessed.",

author = "Raine, {Gary Austin} and Khouja, {Claire Louise} and Meena Khatwa and Melissa Harden and Katy Sutcliffe and Sowden, {Amanda Jayne}",

year = "2023",

month = jan,

language = "English",

publisher = "EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.",

}

TY - BOOK

T1 - Treatment and rehabilitation of Long COVID: A scope of the literature.

T2 - Update January 2023

AU - Raine, Gary Austin

AU - Khouja, Claire Louise

AU - Khatwa, Meena

AU - Harden, Melissa

AU - Sutcliffe, Katy

AU - Sowden, Amanda Jayne

PY - 2023/1

Y1 - 2023/1

N2 - Summary• We identified 12 randomised controlled trials published since September 2022 that were focused on Long COVID treatment or rehabilitation. Across our three reports produced to date, we have identified and assessed 37 trials published between January and December 2022.• Half of the trials included in this update had a primary focus on treating persistent problems with respiratory function and physical fitness (n=6). Other trials focused on olfactory dysfunction (n=2); and cognitive problems and long-term fatigue (n=1). Three trials evaluated non-specific interventions for treating Long COVID symptoms (n=3). • Seven trials were rated positively for at least 11 out of the 13 criteria that we assessed.

AB - Summary• We identified 12 randomised controlled trials published since September 2022 that were focused on Long COVID treatment or rehabilitation. Across our three reports produced to date, we have identified and assessed 37 trials published between January and December 2022.• Half of the trials included in this update had a primary focus on treating persistent problems with respiratory function and physical fitness (n=6). Other trials focused on olfactory dysfunction (n=2); and cognitive problems and long-term fatigue (n=1). Three trials evaluated non-specific interventions for treating Long COVID symptoms (n=3). • Seven trials were rated positively for at least 11 out of the 13 criteria that we assessed.

M3 - Commissioned report

BT - Treatment and rehabilitation of Long COVID: A scope of the literature.

PB - EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.

CY - London

ER -